Assan
Age 42 Β· Male
"βFrom the moment I arrived, I felt hope again. The doctors treated me with skill, honesty, and genuine care.β"
Assan, from Kazakhstan, was diagnosed with diffuse large B-cell lymphoma in late 2023 and relapsed after chemotherapy. He sought advanced treatment abroad and chose CAR-T therapy with GoBroad Healthcare in Beijing. After treatment in early 2025, follow-ups show no lymphoma evidence and his health has steadily improved.
From Relapse to Remission: Assanβs Story of Hope
Assan was first detected with lymphoma involving the stomach in December 2023. Chemotherapy was first administered to him in Singapore. Regular follow-up exams discovered a relapse approximately one year after therapy began, despite the medication's initial efficacy. The stomach was the site of the recurring lesion, and its removal required surgical intervention.
When Assan had his relapse, he started looking for more cutting-edge, affordable therapy options. His web research and an international medical referral portal connected him with hospitals in Israel, Turkey, and China, among other places. He eventually made contact with GoBroad Healthcare Group's Dr. Yajing Zhang after several online consultations.
In his online consultation, "Dr. Zhang thoroughly examined my medical records and explained that CAR-T therapy would be the most suitable option for my condition," Assan recounted. "The treatment plan at GoBroad was not only more affordable but also more clear and professional compared to other centers I contacted."
Assan went to Beijing to start therapy in January 2025. After undergoing CD19 CAR-T cell treatment, he spent around six weeks in the ICU. The treatment proceeded smoothly, and initial evaluations showed encouraging outcomes.
Assan has been making many trips back to China for follow-up appointments since finishing CAR-T therapy. After a year of treatment, his most recent test revealed promising results: the stomach tumor was effectively controlled, and there were no signs of lymphoma cells in the cerebral fluid or bone marrow.
Assan states that he is generally in good physical health. He took extra precautions to prevent becoming sick following CAR-T treatment because his immune system was temporarily weakened. Over time, I made it a point to walk more, exercise more, and track my vitals. My health has steadily improved over the years.
Beyond the results at the clinic, Assan wanted to express his gratitude to the medical and support staff. His treatment and subsequent follow-ups were characterized by "professionalism, patience, and support" from the medical staff, he said. "A challenging journey was considerably easier thanks to the care experience."
After thinking about it, Assan said that he has told other patients looking for sophisticated cellular therapy about GoBroad. It's obvious that CAR-T therapy is GoBroad's forte. I am hopeful as I continue my journey toward long-term remission and grateful for the treatment I received here.
ββFrom the moment I arrived, I felt hope again. The doctors treated me with skill, honesty, and genuine care. Today, I am living a normal life, something I once thought was impossible. I will always be grateful to this hospital and its incredible team.ββ
Why the Family Contacted CancerFax
After relapse in Kazakhstan β having already received treatment in Singapore β Assan needed to identify which international centres had specific, proven experience in CAR-T therapy for relapsed DLBCL, and to evaluate the options clearly before committing to travel and treatment.
Assan's family needed to understand whether CAR-T β specifically CD19-targeted therapy β was the appropriate next step based on his specific disease profile and prior treatment history.
Identifying centres with specific outcomes data in relapsed DLBCL β rather than CAR-T experience generally β required specialist matching knowledge.
Assan actively evaluated multiple international options. Understanding the differences in protocol, cost, experience, and approach helped him make an informed choice.
"Dr. Zhang thoroughly examined my medical records and explained that CAR-T therapy would be the most suitable option for my condition. The treatment plan at GoBroad was not only more affordable but also more clear and professional compared to other centres I contacted."β Assan, Patient
How CancerFax Helped
CancerFax supported Assan's evaluation process by helping him structure his medical records, compare international options, and connect with GoBroad Healthcare Group β ensuring that his case was clearly presented to Dr. Yajing Zhang's team before his arrival in Beijing.
Chemotherapy history from Singapore, surgical reports, pathology, and follow-up imaging were compiled and prepared for review.
GoBroad was evaluated alongside options in Israel and Turkey based on DLBCL CAR-T experience, programme maturity, and treatment approach.
Clinical documents were translated and the consultation with Dr. Yajing Zhang's team at GoBroad was coordinated.
Travel from Kazakhstan to Beijing, accommodation near the hospital, and appointment scheduling were coordinated ahead of Assan's arrival.
Assan's Treatment Journey
From diagnosis in Kazakhstan to CAR-T response in Beijing β key milestones.
Assan was diagnosed with diffuse large B-cell lymphoma (DLBCL) affecting the stomach. Treatment began with chemotherapy in Singapore.
Chemotherapy produced an initial response. Approximately one year later, follow-up testing revealed relapse at the same site. Surgical removal of the recurring lesion was required.
Assan began researching advanced treatment options internationally. After evaluating multiple centres in Israel, Turkey, and China, he made contact with GoBroad Healthcare Group through an international medical referral portal.
Dr. Zhang reviewed Assan's full medical records online. She confirmed that CD19 CAR-T therapy was the most appropriate option for his situation and provided a clear, detailed treatment plan. Assan found this consultation more professional and comprehensive than others he had received.
Assan travelled to Beijing and began the CAR-T process at GoBroad Healthcare Group. Following conditioning chemotherapy, he received CD19 CAR-T cell therapy. He spent approximately six weeks in the ICU during the monitoring phase.
Follow-up testing after one year of treatment showed no lymphoma cells in the cerebrospinal fluid or bone marrow. The stomach tumour was effectively controlled. Assan's physical health has steadily improved, with increasing exercise and monitored vitals.
Every patient's treatment plan is individual. The pathway above describes this specific case β not a blueprint for others. Suitability for each treatment is determined by the treating clinical team based on each patient's individual clinical situation.
Where Assan Is Today
Assan continues to make regular follow-up trips to China for monitoring after completing his CAR-T treatment in early 2025. His most recent testing β after one year of treatment β showed no lymphoma cells in either the cerebrospinal fluid or the bone marrow. The stomach tumour that had required surgical intervention is effectively controlled.
He reports being in good general physical health. After the temporary immune suppression that followed CAR-T treatment, he took active steps to rebuild his fitness β walking more, exercising regularly, and monitoring his vitals. "My health has steadily improved over the years," he says.
Assan has since recommended GoBroad to other patients seeking advanced cellular therapy. He remains on his journey toward long-term remission β and is grateful for the care he received.
β"From the moment I arrived, I felt hope again. The doctors treated me with skill, honesty, and genuine care. A challenging journey was considerably easier thanks to the care experience."ββ Assan, Patient
What Other Families Can Learn
Assan's journey reflects a situation many lymphoma patients and families encounter after relapse β and offers practical guidance for what to consider next.
In relapsed or refractory DLBCL, CAR-T therapy β specifically CD19-targeted approaches β has established evidence and should be evaluated early, before further salvage chemotherapy narrows eligibility.
Assan evaluated centres in three countries before making his decision. The comparison process gave him confidence and led him to the centre that offered the clearest, most professional treatment plan.
Assan's online consultation with Dr. Yajing Zhang before travelling gave him clear answers and a detailed plan. These consultations are not just informational β they are part of the decision-making process.
Post-CAR-T recovery involves temporary immune suppression and a gradual return to physical strength. Assan's commitment to walking, exercise, and monitoring contributed to his improving condition.
Related on CancerFax
Frequently Asked Questions
This patient story reflects an individual treatment journey. Outcomes vary from patient to patient. The information on this page should not be taken as medical advice or a guarantee of similar results. Treatment suitability depends on diagnosis, disease status, prior therapy, molecular findings, overall health, and specialist medical evaluation. Names and identifying details may be modified to protect patient privacy. All clinical decisions must be made in consultation with a qualified, licensed physician with access to the patient's complete medical information.
Need Help Understanding the Next Step?
If you or a loved one is facing a complex cancer diagnosis, relapse, or limited treatment options, CancerFax can help you organise the case, explore relevant hospitals and doctors, and understand whether advanced treatment or clinical trial pathways may be appropriate.
Β© CancerFax Β· Patient navigation and coordination platform. CancerFax is not a medical institution and does not provide medical treatment. All clinical care is provided by independent licensed physicians and hospitals. Patient names and identifying details are modified or anonymised where required to protect privacy. Story shared with documented family consent.